DWTX on Nasdaq
Dogwood Therapeutics, Inc.
American pharmaceutical preparations company based in Alpharetta1
In its 2026 annual report the company says: “We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. Our pipeline is focused on treating chronic neuropathic pain and neuropathy. Our Halneuron® Na v 1.7 modulation program is intended to treat chronic and acute pain disorders.”3 Its shares trade on Nasdaq under the symbol DWTX.1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerDWTX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersAlpharetta, Georgia1
- Incorporated inDE2
- Business address44 Milton Avenue, Alpharetta, Ga 300092
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. Following the closing of the Combination described below, we became the sole owner of Pharmagesic (Holdings) Inc. (“Pharmagesic”) and their wholly owned subsidiary, Wex Pharmaceuticals, Inc. (“Wex”), and Wex’s wholly owned subsidiaries, IWT Bio, Inc. (“IWT”), Wex Medical Corporation (“WMC”), and Wex Medical Limited (“WML”).3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $21.9M | $3.5M |
| General and administrative expenses | $6.1M | $8.7M |
| Total operating expenses | $28.0M | $12.2M |
| Loss from operations | -$28.0M | -$12.2M |
| Loss on debt conversion with related party | -$6.1M | |
| Loss on fixed asset disposal | -$2.7K | |
| Interest income (expense), net | $96.9K | -$92.2K |
| Exchange loss, net | -$27.9K | -$30.8K |
| Total other expense | -$6.1M | -$123.0K |
| Loss before income taxes | -$34.0M | -$12.4M |
| Deferred income tax (expense) benefit | -$221.1K | $503 |
| Net loss | -$34.3M | -$12.3M |
| Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | -$1.3M | -$514.1K |
| Net loss attributable to common stockholders | -$35.5M | -$12.9M |
| Net loss per common share, basic (in dollars per share) | -$7.13 | -$12.52 |
| Net loss per common share, diluted (in dollars per share) | -$7.13 | -$12.52 |
| Weighted average number of shares outstanding - basic (in shares) | 5.0M shares | 1.0M shares |
| Weighted average number of shares outstanding - diluted (in shares) | 5.0M shares | 1.0M shares |
| Foreign currency translation adjustment | $3.3M | -$3.9M |
| Comprehensive loss | -$31.0M | -$16.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 | 2024-09-30 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $6.5M | $14.8M | |||
| Prepaid expenses and other current assets | $1.9M | $1.7M | |||
| Total current assets | $8.4M | $16.5M | |||
| Property and equipment, net | $12.8K | $16.8K | |||
| Right-of-use assets | $163.1K | $205.8K | |||
| Prepaid expenses, long-term | $19.0K | $18.1K | |||
| Goodwill | $12.4M | $11.8M | |||
| Intangible assets | $69.0M | $65.7M | |||
| Deferred issuance costs | $159.0K | ||||
| Total assets | $90.2M | $94.3M | |||
| Accounts payable | $760.9K | $1.2M | |||
| Accrued expenses | $2.2M | $1.9M | |||
| Lease liability, current portion | $56.8K | $49.7K | |||
| Total current liabilities | $3.1M | $3.2M | |||
| Debt with related party, net of issuance costs | $15.4M | ||||
| Lease liability, long-term portion | $105.8K | $154.9K | |||
| Deferred tax liability | $12.1M | $11.3M | |||
| Total liabilities | $15.3M | $30.0M | |||
| Series A Non-Voting Convertible Preferred Stock, $0.0001 par value; 2,104 shares authorized and 2,103.1494 shares issued and no shares outstanding at December 31, 2025 and 2,270 shares authorized and 2,213.8044 shares issued and outstanding at December 31, 2024 | $74.4M | ||||
| Common stock, $0.0001 par value; 43,000,000 shares authorized; 29,751,234 and 29,743,516 shares issued and outstanding at December 31, 2025, respectively; and 1,339,896 and 1,332,178 shares issued and outstanding at December 31, 2024, respectively | $3.0K | $133 | |||
| Additional paid-in capital | $183.9M | $67.9M | |||
| Accumulated deficit | -$108.1M | -$73.8M | |||
| Accumulated other comprehensive loss | -$587.0K | -$3.9M | |||
| Stockholders' equity before treasury stock | $75.2M | -$9.8M | |||
| Less: Treasury stock, 7,718 shares of common stock at cost | -$299.1K | -$299.1K | |||
| Total stockholders' equity (deficit) | $74.9M | -$10.1M | $3.8M | ||
| Total liabilities, Series A Non-Voting Convertible Preferred Stock and stockholders' equity (deficit) | $90.2M | $94.3M | |||
| Temporary equity, par value (in dollars per share) | $0.00 | $0.00 | |||
| Temporary equity, shares authorized | 2.1K shares | 2.3K shares | |||
| Temporary equity, shares issued | 2.1K shares | 2.2K shares | |||
| Temporary equity, shares outstanding | 0 shares | 2.2K shares | |||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Common stock authorized | 43.0M shares | 43.0M shares | |||
| Common stock issued | 29.8M shares | 1.3M shares | 28.0M shares | ||
| Common stock outstanding | 29.7M shares | 1.3M shares | 27.8M shares | ||
| Preferred stock, par value (in dollars per share) | $0.00 | ||||
| Preferred stock authorized | 2.0M shares | 2.0M shares | |||
| Treasury stock | 7.7K shares | 7.7K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 | 2024-09-30 | 2023-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $6.5M | $14.8M | ||||
| Prepaid expenses and other current assets | $1.9M | $1.7M | ||||
| Total current assets | $8.4M | $16.5M | ||||
| Property and equipment, net | $12.8K | $16.8K | ||||
| Right-of-use assets | $163.1K | $205.8K | ||||
| Prepaid expenses, long-term | $19.0K | $18.1K | ||||
| Goodwill | $12.4M | $11.8M | ||||
| Intangible assets | $69.0M | $65.7M | ||||
| Deferred issuance costs | $159.0K | |||||
| Total assets | $90.2M | $94.3M | ||||
| Accounts payable | $760.9K | $1.2M | ||||
| Accrued expenses | $2.2M | $1.9M | ||||
| Lease liability, current portion | $56.8K | $49.7K | ||||
| Total current liabilities | $3.1M | $3.2M | ||||
| Debt with related party, net of issuance costs | $15.4M | |||||
| Lease liability, long-term portion | $105.8K | $154.9K | ||||
| Deferred tax liability | $12.1M | $11.3M | ||||
| Total liabilities | $15.3M | $30.0M | ||||
| Series A Non-Voting Convertible Preferred Stock, $0.0001 par value; 2,104 shares authorized and 2,103.1494 shares issued and no shares outstanding at December 31, 2025 and 2,270 shares authorized and 2,213.8044 shares issued and outstanding at December 31, 2024 | $74.4M | |||||
| Common stock, $0.0001 par value; 43,000,000 shares authorized; 29,751,234 and 29,743,516 shares issued and outstanding at December 31, 2025, respectively; and 1,339,896 and 1,332,178 shares issued and outstanding at December 31, 2024, respectively | $3.0K | $133 | ||||
| Additional paid-in capital | $183.9M | $67.9M | ||||
| Accumulated deficit | -$108.1M | -$73.8M | ||||
| Accumulated other comprehensive loss | -$587.0K | -$3.9M | ||||
| Stockholders' equity before treasury stock | $75.2M | -$9.8M | ||||
| Less: Treasury stock, 7,718 shares of common stock at cost | -$299.1K | -$299.1K | ||||
| Total stockholders' equity (deficit) | $74.9M | -$10.1M | $3.8M | |||
| Total liabilities, Series A Non-Voting Convertible Preferred Stock and stockholders' equity (deficit) | $90.2M | $94.3M | ||||
| Temporary equity, par value (in dollars per share) | $0.00 | $0.00 | ||||
| Temporary equity, shares authorized | 2.1K shares | 2.3K shares | ||||
| Temporary equity, shares issued | 2.1K shares | 2.2K shares | ||||
| Temporary equity, shares outstanding | 0 shares | 2.2K shares | ||||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | $0.00 | |||
| Common stock authorized | 43.0M shares | 43.0M shares | 43.0M shares | |||
| Common stock issued | 29.8M shares | 1.3M shares | 28.0M shares | |||
| Common stock outstanding | 29.7M shares | 1.3M shares | 27.8M shares | |||
| Preferred stock, par value (in dollars per share) | $0.00 | |||||
| Preferred stock authorized | 2.0M shares | 2.0M shares | ||||
| Treasury stock | 7.7K shares | 7.7K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$34.3M | -$12.3M |
| Loss on foreign exchange | $27.9K | $30.8K |
| Loss on fixed asset disposal | $2.7K | |
| Amortization of loan costs | $52.4K | $58.4K |
| Depreciation | $2.1K | $12.2K |
| Reduction in carrying amount of right-of-use asset | $66.1K | |
| Loss on debt conversion with related party | $6.1M | |
| Acquisition of license for research and development | $11.9M | |
| Non-cash transaction costs | $3.6M | |
| Deferred tax expense (benefit) | $221.1K | -$503 |
| Share-based compensation expense | $355.6K | $476.0K |
| Increase in prepaid expenses and other current assets | -$208.7K | -$498.7K |
| (Decrease) increase in accounts payable | -$532.6K | $219.9K |
| Increase (decrease) in accrued expenses and other liabilities | $608.3K | -$302.4K |
| Net cash used in operating activities | -$15.6M | -$8.8M |
| Cash acquired through the acquisition of Pharmagesic | $3.8M | |
| Net cash provided by investing activities | $3.8M | |
| Proceeds from public offering of common stock, net of offering costs | $4.3M | $1.4M |
| Proceeds from loan with related party, net of fees | $3.0M | $15.3M |
| Payout of fractional shares with reverse stock split | -$351 | |
| Proceeds from issuance of shares on ATM, net of cash fees paid | $86.4K | |
| Cash payment of issuance costs | -$53.8K | |
| Net cash provided by financing activities | $7.3M | $16.7M |
| Net (decrease) increase in cash | -$8.3M | $11.7M |
| Effect of foreign currency translation on cash and cash equivalents | $10.6K | -$144.6K |
| Issuance costs included in accounts payable and accrued expenses | $106.3K | |
| Conversion of debt with related party into Series A-1 Non-Voting Convertible Preferred Stock | $19.5M | |
| Conversion of accrued interest on debt with related party into Series A-1 Non-Voting Convertible Preferred Stock | $426.9K | |
| Conversion of Series A Non-Voting Convertible Preferred Stock from temporary equity to permanent equity | $5.5M | |
| Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | $1.3M | $514.1K |
| Preferred stock issued in connection with License Agreement | $9.8M | |
| Common stock issued in connection with License Agreement | $2.1M | |
| Conversion of preferred stock into common stock | $110.5M | |
| Preferred stock issued in connection with acquisition of Pharmagesic | $70.4M | |
| Common stock issued in connection with acquisition of Pharmagesic | $893.1K |
No quarter-by-quarter statement was filed.
Corporate structure
Dogwood Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Dogwood Therapeutics, Inc.
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Dogwood Therapeutics, Inc., latest Aug 14, 2026 (2 filings since May 15, 2026)
- Sealbond Ltd Filed SCHEDULE 13D/A on Dogwood Therapeutics, Inc., latest Nov 25, 2025 (3 filings since Oct 15, 2024)
- Orca Capital AG Filed SCHEDULE 13G/A on Dogwood Therapeutics, Inc., latest Mar 17, 2025 (2 filings since Mar 17, 2025)
- Brian David Corday Filed SC 13G/A on Dogwood Therapeutics, Inc., latest Feb 13, 2024 (7 filings since Dec 21, 2022)
- MASTERS CAPITAL MANAGEMENT LLC Filed SC 13G/A on Dogwood Therapeutics, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Gregory Scott Duncan Filed SC 13G/A on Dogwood Therapeutics, Inc., latest Feb 13, 2023 (2 filings since Feb 14, 2022)
- Ionic Ventures, LLC Filed SC 13G/A on Dogwood Therapeutics, Inc., latest Feb 13, 2023 (2 filings since Sep 21, 2022)
- Richard Alan Burch Filed SC 13G/A on Dogwood Therapeutics, Inc., latest Feb 13, 2023 (2 filings since Feb 14, 2022)
- William Pridgen Filed SC 13G/A on Dogwood Therapeutics, Inc., latest Feb 13, 2023 (2 filings since Feb 14, 2022)
- Dogwood Therapeutics, Inc. Alpharetta, Georgia
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Dogwood Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $12.8K8 Dec 31, 2025 | $18.4K8 Dec 31, 2024 | −30.6% |
| Accumulated depreciation | $1.6K8 Dec 31, 2024 | ||
| Property and equipment, net | $12.8K8 Dec 31, 2025 | $16.8K8 Dec 31, 2024 | −24.1% |
| Operating-lease assets (leased space) | $163.1K8 Dec 31, 2025 | $205.8K8 Dec 31, 2024 | −20.7% |
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $12.4M8 Dec 31, 2025 | $11.8M8 Dec 31, 2024 | +5.0% |
| Intangible assets, net (excluding goodwill) | $69.0M8 Dec 31, 2025 | $65.7M8 Dec 31, 2024 | +5.0% |
Properties, in its own words
We do not own or lease any real property in the United States. We run a virtual model and have a mailing address in Alpharetta, Georgia. We lease office spaces in Vancouver, British Columbia, Canada located at 1150-1100 Melville St, Vancouver B.C., Canada.
Item 2 of the 10-K filed Mar 18, 2026.3
Leadership
Who has led Dogwood Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerGregory Scott Duncan Dec 16, 2020 to now11
- Chief financial officerAngela Walsh Jul 1, 2025 to now12
Board members and other officers (11)
- VP of FinanceAngela Walsh Dec 16, 2020 to Feb 28, 202413
- Vice President of OperationsRalph Grosswald Dec 16, 2020 to now14
- Chief Medical OfficerRoger Michael Gendreau Dec 16, 2020 to now15
- Board memberKean Meng Melvin Toh Oct 17, 2024 to Oct 17, 202416
- Board memberYing Choi Alan Abel Yu Oct 17, 2024 to Oct 17, 202417
- Board memberDavid R. Keefer Dec 16, 2020 to now18
- Board memberGregory Scott Duncan Dec 16, 2020 to now11
- Board memberJohn C. Thomas Dec 16, 2020 to now19
- Board memberRichard James Whitley Dec 16, 2020 to now20
- Board memberWilliam Pridgen Dec 16, 2020 to Feb 28, 202421
- Board memberRichard Alan Burch Dec 17, 2020 to Feb 28, 202422
Former names
Timeline
- Aug 13, 20268-K Results of operations23
- Jun 17, 20268-K Bylaws or fiscal year changed; Shareholder vote24
- May 14, 20268-K Results of operations25
- Mar 26, 20268-K Regulation FD disclosure26
- Mar 18, 20268-K Results of operations27
- Mar 12, 20268-K Shareholder vote28
- Jan 20, 20268-K Regulation FD disclosure29
- Jan 13, 20268-K Entered a material agreement; Ended a material agreement; Unregistered sale of shares30
- Nov 28, 20258-K Entered a material agreement31
- Nov 21, 20258-K Executive or director change; Shareholder vote32
- Nov 6, 20258-K Results of operations33
- Oct 9, 20258-K Regulation FD disclosure34
- Dec 16, 2020New chief executive Gregory Scott Duncan becomes CEO11
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($8.20) a share, on Nov 6, 2025.35
When it reported results
- Aug 13, 2026Reported quarterly or annual results23
- May 14, 2026Reported quarterly or annual results25
- Mar 18, 2026Reported quarterly or annual results27
- Nov 6, 2025Reported quarterly or annual results33
- Aug 13, 2025Reported quarterly or annual results36
- May 8, 2025Reported quarterly or annual results37
- Mar 31, 2025Reported quarterly or annual results38
- Nov 7, 2024Reported quarterly or annual results39
Drug trials and FDA: coming up
- Dec 2026Phase 2 trial readout expected Phase 2 trial of Halneuron and Halneuron (Open Label Extension) in Chemotherapy Induced Neuropathic Pain: primary completion expected Dec 2026 (ClinicalTrials.gov NCT06848348).40
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
240 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 66 major events, 81 insider forms, 24 large holders, 48 other. The latest 20:
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 13, 20268-K EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20268-K EDGAR
- May 15, 2026SCHEDULE 13G EDGAR
- May 15, 202610-Q EDGAR
- May 14, 20268-K EDGAR
- Apr 27, 2026ARS EDGAR
- Apr 27, 2026DEF 14A EDGAR
- Apr 17, 2026PRE 14A EDGAR
- Mar 26, 20268-K EDGAR
- Mar 18, 202610-K EDGAR
- Mar 18, 20268-K EDGAR
- Mar 12, 20268-K EDGAR
- Mar 6, 20264 EDGAR
- Mar 6, 20264 EDGAR
The 240 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
19 open-market trades by officers, directors and large owners since October 2021: 18 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2023 | Pridgen WilliamDirector | Buy | 15,335 | $1.30 | $19.9K | Form 4 |
| Aug 17, 2023 | Duncan Gregory ScottCHIEF EXECUTIVE OFFICER | Buy | 25,000 | $1.25 | $31.2K | Form 4 |
| Dec 8, 2022 | Whitley Richard JamesDirector | Sale | 1,800 | $0.26 | $468 | Form 4 |
| May 23, 2022 | Walsh AngelaChief Financial Officer | Buy | 2,000 | $4.58 | $9.2K | Form 4 |
| May 23, 2022 | Duncan Gregory ScottCHIEF EXECUTIVE OFFICER | Buy | 7,500 | $4.52 | $33.9K | Form 4 |
| May 18, 2022 | Whitley Richard JamesDirector | Buy | 500 | $4.53 | $2.3K | Form 4 |
| May 18, 2022 | Pridgen WilliamDirector | Buy | 241 | $4.50 | $1.1K | Form 4 |
| May 17, 2022 | Pridgen WilliamDirector | Buy | 13,450 | $4.38 | $58.9K | Form 4 |
| Mar 29, 2022 | Pridgen WilliamDirector | Buy | 600 | $4.94 | $3.0K | Form 4 |
| Mar 23, 2022 | Pridgen WilliamDirector | Buy | 2,197 | $5.46 | $12.0K | Form 4 |
| Jan 27, 2022 | Pridgen WilliamDirector | Buy | 4,180 | $5.98 | $25.0K | Form 4 |
| Jan 7, 2022 | De La Rosa AbelDirector | Buy | 4,000 | $5.90 | $23.6K | Form 4 |
| Jan 6, 2022 | Whitley Richard JamesDirector | Buy | 1,800 | $5.72 | $10.3K | Form 4 |
| Jan 4, 2022 | Keefer David RDirector | Buy | 5,000 | $5.80 | $29.0K | Form 4 |
| Jan 4, 2022 | Thomas John CDirector | Buy | 1,000 | $5.65 | $5.7K | Form 4 |
| Jan 3, 2022 | Pridgen WilliamDirector | Buy | 2,215 | $5.43 | $12.0K | Form 4 |
| Dec 23, 2021 | Whitley Richard JamesDirector | Buy | 200 | $5.73 | $1.1K | Form 4 |
| Dec 21, 2021 | Pridgen WilliamDirector | Buy | 8,827 | $5.66 | $50.0K | Form 4 |
| Dec 21, 2021 | Duncan Gregory ScottCHIEF EXECUTIVE OFFICER | Buy | 5,000 | $5.52 | $27.6K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 14, 202641
- Sealbond LtdSCHEDULE 13D/A, 3 filings Oct 15, 2024 to Nov 25, 202542
- Orca Capital AGSCHEDULE 13G/A, 2 filings Mar 17, 202543
- Brian David CordaySC 13G/A, 7 filings Dec 21, 2022 to Feb 13, 202444
- MASTERS CAPITAL MANAGEMENT LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202345
- Gregory Scott DuncanSC 13G/A, 2 filings Feb 14, 2022 to Feb 13, 202346
- Ionic Ventures, LLCSC 13G/A, 2 filings Sep 21, 2022 to Feb 13, 202347
- Richard Alan BurchSC 13G/A, 2 filings Feb 14, 2022 to Feb 13, 202348
- William PridgenSC 13G/A, 2 filings Feb 14, 2022 to Feb 13, 202349
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Greg Duncan | 61 | $577.0K | $3.3M50 |
| 2025 | R. Michael GendreauMD, PhD | $366.1K | $1.3M50 | |
| 2025 | Angela Walsh | 60 | $300.9K | $1.3M50 |
| 2024 | Chairman and Chief Executive Officer | $523.0K | $881.2K50 | |
| 2024 | Chief Medical Officer | $331.8K | $511.6K50 | |
| 2024 | Chief Financial Officer | $239.6K | $364.3K50 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Armistice Capital, LLC | 3,132,486 | $5.0M | 0.1% | −147,514 |
| Millennium Management LLC | 341,814 | $550.3K | 0.0% | New |
| Vanguard Capital Management LLC | 132,154 | $212.8K | 0.0% | No change |
| Geode Capital Management, LLC | 88,298 | $142.2K | 0.0% | +8,864 |
| Vanguard Fiduciary Trust Co | 62,736 | $101.0K | 0.0% | No change |
| BlackRock, Inc. | 28,546 | $46.0K | 0.0% | +28,516 |
| Northern Trust Corp | 23,779 | $38.3K | 0.0% | No change |
| Citadel Advisors LLC | 11,742 | $18.9K | 0.0% | New |
| Tower Research Capital LLC (TRC) | 3,093 | $5.0K | 0.0% | −4,974 |
| Morgan Stanley | 2,222 | $3.6K | 0.0% | New |
| UBS Group AG | 1,860 | $3.0K | 0.0% | −5,225 |
| Jones Financial Companies Lllp | 160 | $264 | 0.0% | New |
| Barclays PLC | 157 | $253 | 0.0% | New |
| Activest Wealth Management | 120 | $193 | 0.0% | No change |
| Group One Trading LLC | 9 | $14 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Dogwood Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARDogwood Therapeutics, Inc.1
- CIK0001818844
- Employer ID (EIN)85-43142013
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address44 Milton Avenue, Alpharetta, GA 300091
- Phone86662086551
- Shares outstanding33,992,553 as of Aug 13, 202610
- Public float$8.1M as of Jun 30, 20253
- AuditorForvis Mazars, LLP, Atlanta, Georgia PCAOB ID 686; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceJul 24, 20201
- Filings323 in all: 4 (99), 8-K (72), 10-Q (17), SC 13G/A (15), 3 (14), CORRESP (11), DEF 14A (9), UPLOAD (9)1
All 34 form types
DEFA14A (7), S-1/A (7), 10-K (6), SC 13G (6), 424B4 (5), PRE 14A (5), 424B5 (4), ARS (4), EFFECT (4), S-3 (4), S-8 (4), FWP (3), 4/A (2), SCHEDULE 13D/A (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), 10-K/A (1), 5 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRSLTR (1), S-1 (1), S-3/A (1), SC 13D (1)
- Latest filingsAnnual report (10-K) Mar 18, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Apr 27, 2026
Latest 8-K (8-K) Aug 13, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 Par Value per Share | DWTX | Nasdaq |
From the cover page of the 10-K filed Mar 18, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Dogwood Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 18, 2026: 63 risks under these headings, as written.3
- Risks Related to Our Financial Position and Need for Additional Capital
- Our recurring losses from operations raise substantial doubt that we will be able to continue as a going concern and our independent registered public accounting firm has issued an audit report that includes an explanatory paragraph referring to the uncertainty regarding our ability to continue as a going concern without additional capital becoming available. This may hinder our ability to obtain future financing.
- We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.
- We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
- Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations.
- We have a limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.
- Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval
- We are heavily dependent on the success of our product candidates which are still under clinical development, and if these candidates do not receive regulatory approval or, if approved, our commercialization efforts are unsuccessful, our business may be harmed.
- We may face future business disruption and related risks resulting from the spread of infectious disease, which could have a material adverse effect on our business.
- Clinical trials are expensive, time-consuming and difficult to design and implement and involve an uncertain outcome.
- The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for Halneuron®, SP16 or any other product candidates we develop in the future, our business will be substantially harmed.
The other 53 risks
- Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.
- Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.
- The market opportunities for Halneuron® and/or SP16, if approved, may be smaller than we anticipate.
- We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.
- Even if we obtain FDA approval for Halneuron®, SP16 or any other product candidate we develop in the future in the United States, we may never obtain approval for or commercialize those product candidates in any other jurisdiction, which would limit our ability to realize their full global market potential.
- Even if we obtain regulatory approval for Halneuron®, SP16 or any other product candidate we develop in the future, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties.
- We may seek a Breakthrough Therapy designation for Halneuron® from the FDA. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.
- Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.
- Risks Related to Commercialization
- We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.
- Our products may be subject to certain legal and regulatory requirements regarding the packaging, distribution, sale, and labeling of medical products in the United States.
- We may face early generic competition for Halneuron®, SP16 or any other products we successfully develop and market.
- The successful commercialization of Halneuron® or any other product candidate we develop in the future will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.
- Even if any of our product candidates we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
- If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing any product candidate that receives regulatory approval.
- A variety of risks associated with operating internationally could materially adversely affect our business.
- Risks Related to Our Dependence on Third Parties
- Our employees and independent contractors, including principal investigators, clinical trial sites, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
- We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of Halneuron® and SP16 and intend to rely on CMOs for the production of commercial supplies. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.
- We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.
- Risks Related to Healthcare Laws and Other Legal Compliance Matters
- Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.
- Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
- Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation.
- We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.
- If we become profitable, our ability to use our net operating loss carryforwards and other tax attributes to offset future taxable income or taxes may be subject to limitations.
- Risks Related to Our Intellectual Property
- Our patents may be challenged in courts or in patent offices which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
- We may become subject to third parties’ claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.
- We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.
- Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.
- If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.
- Intellectual property rights do not address all potential threats to our competitive advantage.
- Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.
- Our proprietary information may be lost, or we may suffer security breaches.
- Risks Related to Our Employees, Managing Our Growth and Our Operations
- Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.
- We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
- We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.
- Our business and operations would suffer in the event of system failures.
- We may be materially adversely affected by currency fluctuations in the United States dollar versus the Canadian dollar.
- Risks Related to Our Common Stock
- If we are unable to maintain listing of our common stock on the Nasdaq Capital Market or another national stock exchange, it may be more difficult for our stockholders to sell their shares of common stock.
- The market price of our common stock is highly volatile, which could result in substantial losses for holders of our common stock.
- We could be subject to securities class action litigation.
- If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- We are subject to significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.
- If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.
- We are a “smaller reporting company” and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
- Provisions in our certificate of incorporation and bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
- Our certificate of incorporation and our bylaws will contain exclusive forum provisions for certain claims, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- Risks Related to the Combination
- If our acquired intangible assets and goodwill become impaired, we may be required to record a significant charge to earnings.
- Our future results will suffer if we do not effectively manage our expanded operations.
Legal proceedings
From time to time, we may be involved in claims that arise during the ordinary course of business. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management’s attention from important business matters and initiatives, negatively impacting our overall operations. We do not currently have any pending litigation to which we are a party or to which our property is subject that we believe to be material. Regardless of the outcome, litigation can be costly and time consuming, and it can divert management’s attention from important business matters and initiatives, negatively impacting our overall operations.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARAngela Walsh, VP of Finance
- 14
- 15
- 16SEC EDGARKean Meng Melvin Toh, Board member
- 17SEC EDGARYing Choi Alan Abel Yu, Board member
- 18SEC EDGARDavid R. Keefer, Board member
- 19SEC EDGARJohn C. Thomas, Board member
- 20SEC EDGARRichard James Whitley, Board member
- 21SEC EDGARWilliam Pridgen, Board member
- 22SEC EDGARRichard Alan Burch, Board member
- 23SEC EDGARResults of operations
- 24
- 25SEC EDGARResults of operations
- 26SEC EDGARRegulation FD disclosure
- 27SEC EDGARResults of operations
- 28SEC EDGARShareholder vote
- 29SEC EDGARRegulation FD disclosure
- 30
- 31SEC EDGAREntered a material agreement
- 32
- 33SEC EDGARResults of operations
- 34SEC EDGARRegulation FD disclosure
- 35NasdaqNasdaq calendar
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50